EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

Xuchen Zhang, Hefeng Zhang, Feng Hou, Tao Fang, Chuantao Zhang, Huiyun Wang, Shanai Song, Hongwei Lan, Yongjie Wang, Helei Hou

World Journal of Surgical Oncology · 2024

DOI: 10.1186/s12957-024-03434-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Xuchen Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong, Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether programmed cell death-1/ligand-1 (PD-1/PD-L1) blockade-based neoadjuvant treatment may benefit locally advanced oncogene-mutant non–small cell lung cancer (NSCLC) patients remains controversial. This retrospective study was designed to observe the efficacy and safety of neoadjuvant PD-1/PD-L1 blockade plus chemotherapy versus chemotherapy and corresponding tyrosine kinase inhibitors (TKIs) in patients with resectable oncogene-positive NSCLC.

Methods

Patients with potential resectable NSCLC harbouring oncogene alterations who had received neoadjuvant treatment were retrospectively recruited, and an oncogene-negative cohort of patients who received neoadjuvant PD-(L)1 blockade-based neoadjuvant treatment was reviewed for comparison during the same period. The primary aim was to observe the treatment efficacy and event-free survival (EFS) of these agents. Safety profile, molecular target, and immunologic factor data, including PD-L1 expression and tumour mutational burden (TMB), were also obtained.

Results

A total of 46 patients were recruited. Thirty-one of them harboured oncogene alterations, including EGFR , KRAS , ERBB2 , ROS1 , MET , RET , ALK , and FGFR3 alterations. Among the oncogene-positive patients, 18 patients received neoadjuvant PD-(L)1 blockade immunotherapy plus chemotherapy (oncogene-positive IO group), 13 patients were treated with neoadjuvant chemotherapy and/or corresponding TKIs or TKIs alone (oncogene-positive chemo/TKIs group), and the other 15 patients were oncogene negative and received neoadjuvant PD-(L)1 blockade plus chemotherapy (oncogene-negative IO group). The pathological complete response (pCR) and major pathological response (MPR) rates were 22.2% (4 of 18) and 44.4% (8 of 18) in the oncogene-positive IO group, 0% ( P = 0.120) and 23.1% (3 of 13) ( P = 0.276) in the oncogene-positive chemo/TKIs group, and 46.7% (7 of 15) ( P = 0.163) and 80.0% (12 of 15) ( P = 0.072) in the oncogene-negative IO group, respectively. By the last follow-up, the median EFS time had not reached in the oncogene-positive IO group, and was 29.5 months in the oncogene-positive chemo/TKIs group and 38.4 months in the oncogene-negative IO group.

Conclusion

Compared with chemotherapy/TKIs treatment, neoadjuvant treatment with PD-(L)1 blockade plus platinum-based chemotherapy was associated with higher pCR/MPR rates in patients with partially resectable oncogene-mutant NSCLC, while the pCR/MPR rates were lower than their oncogene-negative counterparts treated with PD-(L)1 blockade-based treatment. Specifically, oncogene alteration types and other predictors of response to immunotherapy should be taken into account in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedFollow-Up StudiesSurvival RateAdultPrognosisOncogenesProtein Kinase InhibitorsMutationProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Immune checkpoint blockadeNeoadjuvant therapyOncogene-positive non-small cell lung cancerPD-L1Retrospective study

Substanzen

B7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsProtein Kinase InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China.
  • Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China.
  • Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao University, No.59 Haier Road, Qingdao, 266035, China.
  • Department of Oncology, Shengli Oilfield Central Hospital, No.31 Jinan Road, Dongying, Shandong, 257099, China.
  • Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, Shandong, 266031, China.
  • Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China. wyjtgzy@163.com.

Förderung

  • Natural Science Foundation of Shandong
  • Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project

Zitieren

APA

Zhang, X., Zhang, H., Hou, F., Fang, T., Zhang, C., Wang, H., Song, S., Lan, H., Wang, Y., & Hou, H. (2024). Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03434-1

Vancouver

Zhang X, Zhang H, Hou F, Fang T, Zhang C, Wang H, et al. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03434-1

BibTeX
@article{Zhang2024,
  author = {Zhang, Xuchen and Zhang, Hefeng and Hou, Feng and Fang, Tao and Zhang, Chuantao and Wang, Huiyun and Song, Shanai and Lan, Hongwei and Wang, Yongjie and Hou, Helei},
  title = {Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer},
  journal = {World Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1186/s12957-024-03434-1}
}
Kostenlos starten →